Berg, a small Boston-based biotech firm, is
teaming up with an array of prestigious hospitals and research teams to
discover and validate the first-ever clinical bio-marker to diagnose and
treat Pancreatic Cancer. Berg, which was co-founded six years ago by Carl Berg,
the billionaire real-estate tycoon, along with Mitch Gray and Niven
Narain, is looking to upend that business model. Using big data and
artificial intelligence algorithms developed
by Narain, the biotech firm aims to isolate the root causes of many
diseases, including cancer, and develop tailor-made treatment options
for patients.The data crunching led to the development of Berg’s first drug, BPM 31510,
which is in clinical trials. The drug essentially reprograms the
metabolism of the cancer cells, re-teaching them to undergo apoptosis,
or cell death. The cancer cells die off naturally, without the need for
harmful and expensive chemotherapy.
BPM 31510, which may work on a variety of cancers, will be
introduced in the phase II clinical trials for pancreatic cancer at 48
PCRT sites around the world.
No comments:
Post a Comment